J. van den Bergh

First name
J.
Middle name
P.
Last name
van den Bergh
Rasmussen, N. H., Driessen, J. H. M., Kvist, A. V., Souverein, P. C., van den Bergh, J. P., & Vestergaard, P. (2023). Fracture patterns and associated risk factors in pediatric and early adulthood type 1 diabetes: Findings from a nationwide retrospective cohort study. Bone, 180, 116997. http://doi.org/10.1016/j.bone.2023.116997
View
Schene, M. R., Wyers, C. E., Driessen, A. M. H., Souverein, P. C., Gemmeke, M., van den Bergh, J. P., & Willems, H. C. (2023). Imminent fall risk after fracture. Age Ageing, 52. http://doi.org/10.1093/ageing/afad201
View
van Hulten, V., Driessen, J. H. M., Starup-Linde, J. K., Al-Mashhadi, Z. K., Viggers, R., Klungel, O. H., et al. (2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. http://doi.org/10.1111/dom.15220
View
van Dalem, J., Werkman, C., van den Bergh, J. P., Rossi, B., Viggers, R., Eastell, R., et al. (2022). "Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: a population-based cohort study". Diabetes Res Clin Pract, 109993. http://doi.org/10.1016/j.diabres.2022.109993
View
Driessen, J. H., van Onzenoort, H. A., Henry, R. M., Lalmohamed, A., van den Bergh, J. P., Neef, C., et al. (2014). Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone. http://doi.org/10.1016/j.bone.2014.07.030
View
Curtis, E. M., van der Velde, R., Moon, R. J., van den Bergh, J. P., Geusens, P., de Vries, F., et al. (2016). Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status. Bone. http://doi.org/10.1016/j.bone.2016.03.006
View
Driessen, J. H., van den Bergh, J. P., van Onzenoort, H. A., Henry, R. M., Leufkens, H. G., & de Vries, F. (2017). Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.12843
View
Abtahi, S., Burden, A. M., Geusens, P., van den Bergh, J. P., Van Staa, T., & de Vries, F. (2019). The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population-Based Cohort Study. J Am Med Dir Assoc. http://doi.org/10.1016/j.jamda.2019.11.003
View
Abtahi, S., Driessen, J. H. M., Burden, A. M., Souverein, P. C., van den Bergh, J. P., van Staa, T. P., et al. (2020). Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. http://doi.org/10.1136/annrheumdis-2020-218758
View
Abtahi, S., Driessen, J. H. M., Burden, A. M., Souverein, P. C., van den Bergh, J. P., van Staa, T. P., et al. (2021). Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink. Rheumatology (Oxford). http://doi.org/10.1093/rheumatology/keab548
View